RARE - Company ID 0001515673
The table below shows Ultragenyx Pharmaceutical Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $421.00M | $173.73M | $213.58M | $132.94M | $307.58M | $713.53M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $158.00M | $121.80M | $73.39M | $40.45M | $28.43M | $23.09M |
| Inventory | $52.00M | $45.01M | $33.97M | $26.77M | $16.23M | $13.05M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $951.00M |
| $817.12M |
| $732.18M |
| $883.90M |
| $856.60M |
| $1.30B |
| Property, plant & equipment | $244.00M | $265.93M | $290.57M | $259.73M | $141.25M | $73.52M |
| Goodwill | $44.00M | $44.41M | $44.41M | $44.41M | $44.41M | $44.41M |
| Total assets | $1.53B | $1.50B | $1.49B | $1.55B | $1.52B | $1.76B |
| Accounts payable | $31.00M | $38.76M | $42.11M | $43.27M | $17.14M | $12.92M |
| Total current liabilities | $384.00M | $344.15M | $280.44M | $261.21M | $181.37M | $189.61M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $1.60B | $1.24B | $1.22B | $1.19B | $599.84M | $605.18M |
| Retained earnings | -$4.53B | -$3.96B | -$3.39B | -$2.78B | -$2.07B | -$1.62B |
| Total equity | -$80.00M | $255.30M | $275.41M | $352.49M | $922.56M | $1.15B |